Jade Biosciences Inc (JBIO)
Jade Biosciences, Inc. is a NASDAQ-listed biotechnology company focused on developing therapies for inflammation and immunology indications in patients with autoimmune diseases. Its lead program, JADE101, is a monoclonal antibody designed to block the A PRoliferation Inducing Ligand protein and is currently in phase 1 clinical testing. The company also has two earlier-stage candidates, JADE201 and JADE-003, which remain in preclinical development. Jade Biosciences has a collaboration agreement with Paragon Therapeutics, Inc. The company is based in Waltham, Massachusetts.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-JBIO
|
$13.02
|
-7.7% Downside
|
Fair
|
$50.13
|
255.5% Upside
|
Bargain
|
Good
|
0.0%
|
November 16, 2026
|
2.0x
|
896.7 M
|
436.9 M
|
0.1%
|
81.7%
|
17.0
|
99.3%
|
